Top

Published in:

01-03-2015

Proteomics of ovarian cancer: functional insights and clinical applications

Authors: Mohamed A. Elzek, Karin D. Rodland

Published in: Cancer and Metastasis Reviews | Issue 1/2015

Abstract

In the past decade, there has been an increasing interest in applying proteomics to assist in understanding the pathogenesis of ovarian cancer, elucidating the mechanism of drug resistance, and in the development of biomarkers for early detection of ovarian cancer. Although ovarian cancer is a spectrum of different diseases, the strategies for diagnosis and treatment with surgery and adjuvant therapy are similar across ovarian cancer types, increasing the general applicability of discoveries made through proteomics research. While proteomic experiments face many difficulties which slow the pace of clinical applications, recent advances in proteomic technology contribute significantly to the identification of aberrant proteins and networks which can serve as targets for biomarker development and individualized therapies. This review provides a summary of the literature on proteomics’ contributions to ovarian cancer research and highlights the current issues, future directions, and challenges. We propose that protein-level characterization of primary lesion in ovarian cancer can decipher the mystery of this disease, improve diagnostic tools, and lead to more effective screening programs.

Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(1), 9–29. doi:10.3322/caac.21208.

Schaner, M. E., Ross, D. T., Ciaravino, G., Sorlie, T., Troyanskaya, O., Diehn, M., et al. (2003). Gene expression patterns in ovarian carcinomas. Molecular Biology of the Cell, 14(11), 4376–4386. doi:10.1091/mbc.E03-05-0279.PubMedPubMedCentralCrossRef

Kobel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., et al. (2008). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Medicine, 5(12), e232. doi:10.1371/journal.pmed.0050232.PubMedPubMedCentralCrossRef

Singer, G., Kurman, R. J., Chang, H. W., Cho, S. K., & Shih Ie, M. (2002). Diverse tumorigenic pathways in ovarian serous carcinoma. American Journal of Pathology, 160(4), 1223–1228.PubMedPubMedCentralCrossRef

Kurman, R. J., & Shih Ie, M. (2011). Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Human Pathology, 42(7), 918–931. doi:10.1016/j.humpath.2011.03.003.PubMedPubMedCentralCrossRef

Integrated genomic analyses of ovarian carcinoma (2011). Nature, 474(7353), 609–615. doi:10.1038/nature10166.

Landen, C. N., Jr., Birrer, M. J., & Sood, A. K. (2008). Early events in the pathogenesis of epithelial ovarian cancer. Journal of Clinical Oncology, 26(6), 995–1005. doi:10.1200/jco.2006.07.9970.PubMedCrossRef

Dubeau, L. (1999). The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecologic Oncology, 72(3), 437–442. doi:10.1006/gyno.1998.5275.PubMedCrossRef

Dubeau, L. (2008). The cell of origin of ovarian epithelial tumours. Lancet Oncology, 9(12), 1191–1197. doi:10.1016/s1470-2045(08)70308-5.PubMedCrossRef

10.

Kurman, R. J., & Shih Ie, M. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology, 34(3), 433–443. doi:10.1097/PAS.0b013e3181cf3d79.PubMedPubMedCentralCrossRef

11.

Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., et al. (2007). Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. American Journal of Surgical Pathology, 31(2), 161–169. doi:10.1097/01.pas.0000213335.40358.47.PubMedCrossRef

12.

Crum, C. P., Drapkin, R., Kindelberger, D., Medeiros, F., Miron, A., & Lee, Y. (2007). Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clinical Medicine & Research, 5(1), 35–44. doi:10.3121/cmr.2007.702.CrossRef

13.

Nik, N. N., Vang, R., Shih Ie, M., & Kurman, R. J. (2014). Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annual Review of Pathology, 9, 27–45. doi:10.1146/annurev-pathol-020712-163949.PubMedCrossRef

14.

Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., et al. (2011). Global quantification of mammalian gene expression control. Nature, 473(7347), 337–342. doi:10.1038/nature10098.PubMedCrossRef

15.

Wu, L., Candille, S. I., Choi, Y., Xie, D., Jiang, L., Li-Pook-Than, J., et al. (2013). Variation and genetic control of protein abundance in humans. Nature, 499(7456), 79–82. doi:10.1038/nature12223.PubMedPubMedCentralCrossRef

16.

Ellis, M. J., Gillette, M., Carr, S. A., Paulovich, A. G., Smith, R. D., Rodland, K. K., et al. (2013). Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discovery, 3(10), 1108–1112. doi:10.1158/2159-8290.cd-13-0219.PubMedPubMedCentralCrossRef

17.

Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., et al. (2014). Proteogenomic characterization of human colon and rectal cancer. Nature, 513(7518), 382–387. doi:10.1038/nature13438.PubMedPubMedCentralCrossRef

18.

Chevalier, F. (2010). Highlights on the capacities of “gel-based” proteomics. Proteome Science, 8, 23. doi:10.1186/1477-5956-8-23.PubMedPubMedCentralCrossRef

19.

Spurrier, B., Ramalingam, S., & Nishizuka, S. (2008). Reverse-phase protein lysate microarrays for cell signaling analysis. Nature Protocols, 3(11), 1796–1808. doi:10.1038/nprot.2008.179.PubMedCrossRef

20.

Aebersold, R., & Mann, M. (2003). Mass spectrometry-based proteomics. Nature, 422(6928), 198–207. doi:10.1038/nature01511.PubMedCrossRef

21.

Yates, J. R., Ruse, C. I., & Nakorchevsky, A. (2009). Proteomics by mass spectrometry: approaches, advances, and applications. Annual Review of Biomedical Engineering, 11, 49–79. doi:10.1146/annurev-bioeng-061008-124934.PubMedCrossRef

22.

Bantscheff, M., Lemeer, S., Savitski, M. M., & Kuster, B. (2012). Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Analytical and Bioanalytical Chemistry, 404(4), 939–965. doi:10.1007/s00216-012-6203-4.PubMedCrossRef

23.

Gustafsson, O. J., Arentz, G., & Hoffmann, P. (2014). Proteomic developments in the analysis of formalin-fixed tissue. Biochimica et Biophysica Acta. doi:10.1016/j.bbapap.2014.10.003.PubMedCentral

24.

Lawrie, L. C., Curran, S., McLeod, H. L., Fothergill, J. E., & Murray, G. I. (2001). Application of laser capture microdissection and proteomics in colon cancer. Molecular Pathology, 54(4), 253–258.PubMedPubMedCentralCrossRef

25.

Espina, V., Wulfkuhle, J. D., Calvert, V. S., VanMeter, A., Zhou, W., Coukos, G., et al. (2006). Laser-capture microdissection. Nature Protocols, 1(2), 586–603. doi:10.1038/nprot.2006.85.PubMedCrossRef

26.

Fowler, C. B., O’Leary, T. J., & Mason, J. T. (2013). Toward improving the proteomic analysis of formalin-fixed, paraffin-embedded tissue. Expert Review of Proteomics, 10(4), 389–400. doi:10.1586/14789450.2013.820531.PubMedCrossRef

27.

Konstantinopoulos, P. A., Spentzos, D., & Cannistra, S. A. (2008). Gene-expression profiling in epithelial ovarian cancer. Nature Clinical Practice Oncology, 5(10), 577–587. doi:10.1038/ncponc1178.PubMedCrossRef

28.

Zorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V., Awtrey, C. S., Gardner, G. J., et al. (2005). Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clinical Cancer Research, 11(18), 6422–6430. doi:10.1158/1078-0432.ccr-05-0508.PubMedCrossRef

29.

Bonome, T., Lee, J. Y., Park, D. C., Radonovich, M., Pise-Masison, C., Brady, J., et al. (2005). Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Research, 65(22), 10602–10612. doi:10.1158/0008-5472.can-05-2240.PubMedCrossRef

30.

Morita, A., Miyagi, E., Yasumitsu, H., Kawasaki, H., Hirano, H., & Hirahara, F. (2006). Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics, 6(21), 5880–5890. doi:10.1002/pmic.200500708.PubMedCrossRef

31.

Longuespee, R., Gagnon, H., Boyon, C., Strupat, K., Dauly, C., Kerdraon, O., et al. (2013). Proteomic analyses of serous and endometrioid epithelial ovarian cancers—cases studies—molecular insights of a possible histological etiology of serous ovarian cancer. Proteomics - Clinical Applications, 7(5–6), 337–354. doi:10.1002/prca.201200079.PubMedCrossRef

32.

Jia, L., Zhang, H., Qu, X., Deng, B., & Kong, B. (2012). Proteomic analysis reflects different histologic subtypes of epithelial ovarian cancer. Medical Hypotheses, 78(3), 407–409. doi:10.1016/j.mehy.2011.11.017.PubMedCrossRef

33.

Wiegand, K. C., Hennessy, B. T., Leung, S., Wang, Y., Ju, Z., McGahren, M., et al. (2014). A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer, 14, 120. doi:10.1186/1471-2407-14-120.PubMedPubMedCentralCrossRef

34.

An, H. J., Kim, D. S., Park, Y. K., Kim, S. K., Choi, Y. P., Kang, S., et al. (2006). Comparative proteomics of ovarian epithelial tumors. Journal of Proteome Research, 5(5), 1082–1090. doi:10.1021/pr050461p.PubMedCrossRef

35.

Sereni, M. I., Baldelli, E., Gambara, G., Zanotti, L., Bandiera, E., Bignotti, E., et al. (2014). Functional characterization of epithelial ovarian cancer histotypes by drug target-based protein signaling activation mapping: implications for personalized cancer therapy. Proteomics. doi:10.1002/pmic.201400214.

36.

Toyama, A., Suzuki, A., Shimada, T., Aoki, C., Aoki, Y., Umino, Y., et al. (2012). Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Science, 103(4), 747–755. doi:10.1111/j.1349-7006.2012.02224.x.PubMedCrossRef

37.

Zhu, Y., Wu, R., Sangha, N., Yoo, C., Cho, K. R., Shedden, K. A., et al. (2006). Classifications of ovarian cancer tissues by proteomic patterns. Proteomics, 6(21), 5846–5856. doi:10.1002/pmic.200600165.PubMedCrossRef

38.

Tian, Y., Yao, Z., Roden, R. B., & Zhang, H. (2011). Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics, 11(24), 4677–4687. doi:10.1002/pmic.201000811.PubMedPubMedCentralCrossRef

39.

Mann, M., & Jensen, O. N. (2003). Proteomic analysis of post-translational modifications. Nature Biotechnology, 21(3), 255–261. doi:10.1038/nbt0303-255.PubMedCrossRef

40.

Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S., & Brunak, S. (2004). Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics, 4(6), 1633–1649. doi:10.1002/pmic.200300771.PubMedCrossRef

41.

Abbott, K. L., Lim, J. M., Wells, L., Benigno, B. B., McDonald, J. F., & Pierce, M. (2010). Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics, 10(3), 470–481. doi:10.1002/pmic.200900537.PubMedCrossRef

42.

Shetty, V., Hafner, J., Shah, P., Nickens, Z., & Philip, R. (2012). Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clinical Proteomics, 9(1), 10. doi:10.1186/1559-0275-9-10.PubMedPubMedCentralCrossRef

43.

Kuzmanov, U., Musrap, N., Kosanam, H., Smith, C. R., Batruch, I., Dimitromanolakis, A., et al. (2013). Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. Clinical Chemistry and Laboratory Medicine, 51(7), 1467–1476. doi:10.1515/cclm-2012-0642.PubMedCrossRef

44.

Fila, J., & Honys, D. (2012). Enrichment techniques employed in phosphoproteomics. Amino Acids, 43(3), 1025–1047. doi:10.1007/s00726-011-1111-z.PubMedPubMedCentralCrossRef

45.

Longuespee, R., Boyon, C., Desmons, A., Vinatier, D., Leblanc, E., Farre, I., et al. (2012). Ovarian cancer molecular pathology. Cancer Metastasis Reviews, 31(3–4), 713–732. doi:10.1007/s10555-012-9383-7.PubMedCrossRef

46.

Cohen, J. G., White, M., Cruz, A., & Farias-Eisner, R. (2014). In 2014, can we do better than CA125 in the early detection of ovarian cancer? World Journal of Biological Chemistry, 5(3), 286–300. doi:10.4331/wjbc.v5.i3.286.PubMedPubMedCentralCrossRef

47.

Yin, B. W., & Lloyd, K. O. (2001). Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. Journal of Biological Chemistry, 276(29), 27371–27375. doi:10.1074/jbc.M103554200.PubMedCrossRef

48.

Bast, R. C., Jr., Urban, N., Shridhar, V., Smith, D., Zhang, Z., Skates, S., et al. (2002). Early detection of ovarian cancer: promise and reality. Cancer Treatment and Research, 107, 61–97.PubMed

49.

Fleming, N. D., Cass, I., Walsh, C. S., Karlan, B. Y., & Li, A. J. (2011). CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecologic Oncology, 121(2), 249–252. doi:10.1016/j.ygyno.2011.01.014.PubMedCrossRef

50.

Bast, R. C., Jr., Badgwell, D., Lu, Z., Marquez, R., Rosen, D., Liu, J., et al. (2005). New tumor markers: CA125 and beyond. International Journal of Gynecological Cancer, 15(Suppl 3), 274–281. doi:10.1111/j.1525-1438.2005.00441.x.PubMedCrossRef

51.

Drapkin, R., von Horsten, H. H., Lin, Y., Mok, S. C., Crum, C. P., Welch, W. R., et al. (2005). Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Research, 65(6), 2162–2169. doi:10.1158/0008-5472.can-04-3924.PubMedCrossRef

52.

Hellstrom, I., Raycraft, J., Hayden-Ledbetter, M., Ledbetter, J. A., Schummer, M., McIntosh, M., et al. (2003). The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research, 63(13), 3695–3700.PubMed

53.

Moore, R. G., Miller, M. C., Steinhoff, M. M., Skates, S. J., Lu, K. H., Lambert-Messerlian, G., et al. (2012). Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. American Journal of Obstetrics and Gynecology, 206(4), 351 e351–358. doi:10.1016/j.ajog.2011.12.029.

54.

Montagnana, M., Danese, E., Giudici, S., Franchi, M., Guidi, G. C., Plebani, M., et al. (2011). HE4 in ovarian cancer: from discovery to clinical application. Advances in Clinical Chemistry, 55, 1–20.PubMedCrossRef

55.

Moore, R. G., Miller, M. C., Disilvestro, P., Landrum, L. M., Gajewski, W., Ball, J. J., et al. (2011). Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstetrics and Gynecology, 118(2 Pt 1), 280–288. doi:10.1097/AOG.0b013e318224fce2.PubMedPubMedCentralCrossRef

56.

Nolen, B., Velikokhatnaya, L., Marrangoni, A., De Geest, K., Lomakin, A., Bast, R. C., Jr., et al. (2010). Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecologic Oncology, 117(3), 440–445. doi:10.1016/j.ygyno.2010.02.005.PubMedPubMedCentralCrossRef

57.

Escudero, J. M., Auge, J. M., Filella, X., Torne, A., Pahisa, J., & Molina, R. (2011). Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clinical Chemistry, 57(11), 1534–1544. doi:10.1373/clinchem.2010.157073.PubMedCrossRef

58.

Van Gorp, T., Cadron, I., Despierre, E., Daemen, A., Leunen, K., Amant, F., et al. (2011). HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer, 104(5), 863–870. doi:10.1038/sj.bjc.6606092.PubMedPubMedCentralCrossRef

59.

Montagnana, M., Danese, E., Ruzzenente, O., Bresciani, V., Nuzzo, T., Gelati, M., et al. (2011). The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clinical Chemistry and Laboratory Medicine, 49(3), 521–525. doi:10.1515/cclm.2011.075.PubMedCrossRef

60.

Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., et al. (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology, 112(1), 40–46. doi:10.1016/j.ygyno.2008.08.031.PubMedPubMedCentralCrossRef

61.

Rodland, K. D., & Maihle, N. J. (2010). Searching for a system: the quest for ovarian cancer biomarkers. Cancer Biomarkers, 8(4–5), 223–230. doi:10.3233/cbm-2011-0216.PubMed

62.

Zhang, B., Cai, F. F., & Zhong, X. Y. (2011). An overview of biomarkers for the ovarian cancer diagnosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 158(2), 119–123. doi:10.1016/j.ejogrb.2011.04.023.PubMedCrossRef

63.

Zhang, Z., Bast, R. C., Jr., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., et al. (2004). Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Research, 64(16), 5882–5890. doi:10.1158/0008-5472.can-04-0746.PubMedCrossRef

64.

Ueland, F. R., Desimone, C. P., Seamon, L. G., Miller, R. A., Goodrich, S., Podzielinski, I., et al. (2011). Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstetrics and Gynecology, 117(6), 1289–1297. doi:10.1097/AOG.0b013e31821b5118.PubMedCrossRef

65.

Vernooij, F., Heintz, P., Witteveen, E., & van der Graaf, Y. (2007). The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecologic Oncology, 105(3), 801–812. doi:10.1016/j.ygyno.2007.02.030.PubMedCrossRef

66.

Wegdam, W., Argmann, C. A., Kramer, G., Vissers, J. P., Buist, M. R., Kenter, G. G., et al. (2014). Label-free LC-MSe in tissue and Serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors. PLoS One, 9(9), e108046. doi:10.1371/journal.pone.0108046.PubMedPubMedCentralCrossRef

67.

Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K., Reddy, S., & Farias-Eisner, R. (2005). Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics, 5(17), 4589–4596. doi:10.1002/pmic.200500093.PubMedCrossRef

68.

Ahmed, N., Oliva, K. T., Barker, G., Hoffmann, P., Reeve, S., Smith, I. A., et al. (2005). Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics, 5(17), 4625–4636. doi:10.1002/pmic.200401321.PubMedCrossRef

69.

Pan, S., Chen, R., Aebersold, R., & Brentnall, T. A. (2011). Mass spectrometry based glycoproteomics—from a proteomics perspective. Molecular and Cellular Proteomics, 10(1), R110 003251. doi:10.1074/mcp.R110.003251.PubMedPubMedCentralCrossRef

70.

Faca, V. M., Ventura, A. P., Fitzgibbon, M. P., Pereira-Faca, S. R., Pitteri, S. J., Green, A. E., et al. (2008). Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One, 3(6), e2425. doi:10.1371/journal.pone.0002425.PubMedPubMedCentralCrossRef

71.

Gunawardana, C. G., Kuk, C., Smith, C. R., Batruch, I., Soosaipillai, A., & Diamandis, E. P. (2009). Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. Journal of Proteome Research, 8(10), 4705–4713. doi:10.1021/pr900411g.PubMedCrossRef

72.

Zhang, Y., Xu, B., Liu, Y., Yao, H., Lu, N., Li, B., et al. (2012). The ovarian cancer-derived secretory/releasing proteome: a repertoire of tumor markers. Proteomics, 12(11), 1883–1891. doi:10.1002/pmic.201100654.PubMedCrossRef

73.

Gortzak-Uzan, L., Ignatchenko, A., Evangelou, A. I., Agochiya, M., Brown, K. A., St Onge, P., et al. (2008). A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. Journal of Proteome Research, 7(1), 339–351. doi:10.1021/pr0703223.PubMedCrossRef

74.

Kuk, C., Kulasingam, V., Gunawardana, C. G., Smith, C. R., Batruch, I., & Diamandis, E. P. (2009). Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Molecular and Cellular Proteomics, 8(4), 661–669. doi:10.1074/mcp. M800313-MCP200.PubMedPubMedCentralCrossRef

75.

Kristjansdottir, B., Levan, K., Partheen, K., Carlsohn, E., & Sundfeldt, K. (2013). Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ. Clinical Proteomics, 10(1), 4. doi:10.1186/1559-0275-10-4.PubMedPubMedCentralCrossRef

76.

Davidson, B., Espina, V., Steinberg, S. M., Florenes, V. A., Liotta, L. A., Kristensen, G. B., et al. (2006). Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clinical Cancer Research, 12(3 Pt 1), 791–799. doi:10.1158/1078-0432.ccr-05-2516.PubMedCrossRef

77.

Petri, A. L., Simonsen, A. H., Yip, T. T., Hogdall, E., Fung, E. T., Lundvall, L., et al. (2009). Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstetricia et Gynecologica Scandinavica, 88(1), 18–26. doi:10.1080/00016340802443830.PubMedCrossRef

78.

Moyer, V. A. (2012). Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Annals of Internal Medicine, 157(12), 900–904. doi:10.7326/0003-4819-157-11-201212040-00539.PubMedCrossRef

79.

American College of, O., & Gynecologists Committee on Gynecologic, P. (2011). Committee Opinion No. 477: the role of the obstetrician–gynecologist in the early detection of epithelial ovarian cancer. Obstetrics and Gynecology, 117(3), 742–746. doi:10.1097/AOG.0b013e31821477db.CrossRef

80.

Buys, S. S., Partridge, E., Black, A., Johnson, C. C., Lamerato, L., Isaacs, C., et al. (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA, 305(22), 2295–2303. doi:10.1001/jama.2011.766.PubMedCrossRef

81.

Kobayashi, H., Yamada, Y., Sado, T., Sakata, M., Yoshida, S., Kawaguchi, R., et al. (2008). A randomized study of screening for ovarian cancer: a multicenter study in Japan. International Journal of Gynecological Cancer, 18(3), 414–420. doi:10.1111/j.1525-1438.2007.01035.x.PubMedCrossRef

82.

Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology, 10(4), 327–340. doi:10.1016/s1470-2045(09)70026-9.PubMedCrossRef

83.

Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., et al. (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 21(17), 3194–3200. doi:10.1200/jco.2003.02.153.PubMedCrossRef

84.

Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012). Therapeutic strategies in epithelial ovarian cancer. Journal of Experimental & Clinical Cancer Research, 31, 14. doi:10.1186/1756-9966-31-14.CrossRef

85.

Fountain, J., Trimble, E., & Birrer, M. J. (2006). Summary and discussion of session recommendations. Gynecologic Oncology, 103(2 Suppl 1), S23–S25. doi:10.1016/j.ygyno.2006.08.022.PubMed

86.

Hartmann, L. C., Lu, K. H., Linette, G. P., Cliby, W. A., Kalli, K. R., Gershenson, D., et al. (2005). Gene expression profiles predict early relapse in ovarian cancer after platinum–paclitaxel chemotherapy. Clinical Cancer Research, 11(6), 2149–2155. doi:10.1158/1078-0432.ccr-04-1673.PubMedCrossRef

87.

Berchuck, A., Iversen, E. S., Lancaster, J. M., Dressman, H. K., West, M., Nevins, J. R., et al. (2004). Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. American Journal of Obstetrics and Gynecology, 190(4), 910–925. doi:10.1016/j.ajog.2004.02.005.PubMedCrossRef

88.

Spentzos, D., Levine, D. A., Ramoni, M. F., Joseph, M., Gu, X., Boyd, J., et al. (2004). Gene expression signature with independent prognostic significance in epithelial ovarian cancer. Journal of Clinical Oncology, 22(23), 4700–4710. doi:10.1200/jco.2004.04.070.PubMedCrossRef

89.

Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., et al. (2006). Genomic signatures to guide the use of chemotherapeutics. Nature Medicine, 12(11), 1294–1300. doi:10.1038/nm1491.PubMedCrossRef

90.

Agarwal, R., & Kaye, S. B. (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Reviews Cancer, 3(7), 502–516. doi:10.1038/nrc1123.PubMedCrossRef

91.

Li, S.-L., Ye, F., Cai, W.-J., Hu, H.-D., Hu, P., Ren, H., et al. (2010). Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. Journal of Cellular Biochemistry, 109(4), 625–633. doi:10.1002/jcb.22413.PubMed

92.

Yan, X. D., Pan, L. Y., Yuan, Y., Lang, J. H., & Mao, N. (2007). Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. Journal of Proteome Research, 6(2), 772–780. doi:10.1021/pr060402r.PubMedCrossRef

93.

Di Michele, M., Marcone, S., Cicchillitti, L., Della Corte, A., Ferlini, C., Scambia, G., et al. (2010). Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. Journal of Proteomics, 73(5), 879–898. doi:10.1016/j.jprot.2009.11.012.PubMedCrossRef

94.

Dai, Z., Yin, J., He, H., Li, W., Hou, C., Qian, X., et al. (2010). Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics, 10(21), 3789–3799. doi:10.1002/pmic.200900685.PubMedCrossRef

95.

Lee, D. H., Chung, K., Song, J. A., Kim, T. H., Kang, H., Huh, J. H., et al. (2010). Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. Journal of Proteome Research, 9(11), 5668–5676. doi:10.1021/pr100478u.PubMedCrossRef

96.

Chappell, N. P., Teng, P. N., Hood, B. L., Wang, G., Darcy, K. M., Hamilton, C. A., et al. (2012). Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. Journal of Proteome Research, 11(9), 4605–4614. doi:10.1021/pr300403d.PubMedCrossRef

97.

Chen, X., Wei, S., Ma, Y., Lu, J., Niu, G., Xue, Y., et al. (2014). Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer. Theranostics, 4(12), 1164–1175. doi:10.7150/thno.8502.PubMedPubMedCentralCrossRef

98.

Cicchillitti, L., Di Michele, M., Urbani, A., Ferlini, C., Donat, M. B., Scambia, G., et al. (2009). Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. Journal of Proteome Research, 8(4), 1902–1912.PubMedCrossRef

99.

Le Moguen, K., Lincet, H., Marcelo, P., Lemoisson, E., Heutte, N., Duval, M., et al. (2007). A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment. Proteomics, 7(22), 4090–4101. doi:10.1002/pmic.200700231.PubMedCrossRef

100.

Yang, J. Y., Yoshihara, K., Tanaka, K., Hatae, M., Masuzaki, H., Itamochi, H., et al. (2013). Predicting time to ovarian carcinoma recurrence using protein markers. Journal of Clinical Investigation, 123(9), 3740–3750. doi:10.1172/jci68509.PubMedPubMedCentralCrossRef

101.

Lee, J. M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L., Zujewski, J. A., et al. (2014). Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. Journal of the National Cancer Institute, 106(6), dju089. doi:10.1093/jnci/dju089.PubMedPubMedCentralCrossRef

102.

Carey, M. S., Agarwal, R., Gilks, B., Swenerton, K., Kalloger, S., Santos, J., et al. (2010). Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF–beta pathway signaling indicates response to primary chemotherapy. Clinical Cancer Research, 16(10), 2852–2860. doi:10.1158/1078-0432.ccr-09-2502.PubMedPubMedCentralCrossRef

103.

Picotti, P., Lam, H., Campbell, D., Deutsch, E. W., Mirzaei, H., Ranish, J., et al. (2008). A database of mass spectrometric assays for the yeast proteome. Nature Methods, 5(11), 913–914. doi:10.1038/nmeth1108-913.PubMedPubMedCentralCrossRef

104.

Chen, Y., Gruidl, M., Remily-Wood, E., Liu, R. Z., Eschrich, S., Lloyd, M., et al. (2010). Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. Journal of Proteome Research, 9(8), 4215–4227. doi:10.1021/pr1005197.PubMedPubMedCentralCrossRef

105.

Schrader, M., Schulz-Knappe, P., & Fricker, L. D. (2014). Historical perspective of peptidomics. EuPA Open Proteomics, 3, 171–182. doi:10.1016/j.euprot.2014.02.014.CrossRef

106.

Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A., Erdjument-Bromage, H., Olshen, A. B., et al. (2006). Differential exoprotease activities confer tumor-specific serum peptidome patterns. Journal of Clinical Investigation, 116(1), 271–284. doi:10.1172/jci26022.PubMedPubMedCentralCrossRef

107.

Lopez, M. F., Mikulskis, A., Kuzdzal, S., Golenko, E., Petricoin, E. F., 3rd, Liotta, L. A., et al. (2007). A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clinical Chemistry, 53(6), 1067–1074. doi:10.1373/clinchem.2006.080721.PubMedCrossRef

108.

Fredolini, C., Meani, F., Luchini, A., Zhou, W., Russo, P., Ross, M., et al. (2010). Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. The AAPS Journal, 12(4), 504–518. doi:10.1208/s12248-010-9211-3.PubMedPubMedCentralCrossRef

109.

Xu, Z., Wu, C., Xie, F., Slysz, G. W., Tolic, N., Monroe, M. E., et al. (2014). Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. Journal of Proteome Research. doi:10.1021/pr500840w.

110.

Pan, B. T., & Johnstone, R. M. (1983). Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell, 33(3), 967–978.PubMedCrossRef

111.

Ciechanover, A., Schwartz, A. L., Dautry-Varsat, A., & Lodish, H. F. (1983). Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. Journal of Biological Chemistry, 258(16), 9681–9689.PubMed

112.

E. L. A, S., Mager, I., Breakefield, X. O., & Wood, M. J. (2013). Extracellular vesicles: biology and emerging therapeutic opportunities. Nature Reviews Drug Discovery, 12(5), 347–357. doi:10.1038/nrd3978.CrossRef

113.

Azmi, A. S., Bao, B., & Sarkar, F. H. (2013). Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Reviews, 32(3–4), 623–642. doi:10.1007/s10555-013-9441-9.PubMedCrossRef

114.

Chairoungdua, A., Smith, D. L., Pochard, P., Hull, M., & Caplan, M. J. (2010). Exosome release of beta-catenin: a novel mechanism that antagonizes Wnt signaling. Journal of Cell Biology, 190(6), 1079–1091. doi:10.1083/jcb.201002049.PubMedPubMedCentralCrossRef

115.

Cho, J. A., Park, H., Lim, E. H., & Lee, K. W. (2012). Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. International Journal of Oncology, 40(1), 130–138. doi:10.3892/ijo.2011.1193.PubMed

116.

Shedden, K., Xie, X. T., Chandaroy, P., Chang, Y. T., & Rosania, G. R. (2003). Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Research, 63(15), 4331–4337.PubMed

117.

Safaei, R., Larson, B. J., Cheng, T. C., Gibson, M. A., Otani, S., Naerdemann, W., et al. (2005). Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Molecular Cancer Therapeutics, 4(10), 1595–1604. doi:10.1158/1535-7163.mct-05-0102.PubMedCrossRef

118.

Beach, A., Zhang, H. G., Ratajczak, M. Z., & Kakar, S. S. (2014). Exosomes: an overview of biogenesis, composition and role in ovarian cancer. Journal of Ovarian Research, 7(1), 14. doi:10.1186/1757-2215-7-14.PubMedPubMedCentralCrossRef

119.

Sinha, A., Ignatchenko, V., Ignatchenko, A., Mejia-Guerrero, S., & Kislinger, T. (2014). In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome. Biochemical and Biophysical Research Communications, 445(4), 694–701. doi:10.1016/j.bbrc.2013.12.070.PubMedCrossRef

120.

Pisitkun, T., Gandolfo, M. T., Das, S., Knepper, M. A., & Bagnasco, S. M. (2012). Application of systems biology principles to protein biomarker discovery: urinary exosomal proteome in renal transplantation. Proteomics - Clinical Applications, 6(5–6), 268–278. doi:10.1002/prca.201100108.PubMedCrossRef

121.

Kalra, H., Adda, C. G., Liem, M., Ang, C. S., Mechler, A., Simpson, R. J., et al. (2013). Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics, 13(22), 3354–3364. doi:10.1002/pmic.201300282.PubMedCrossRef

122.

Zubiri, I., Vivanco, F., & Alvarez-Llamas, G. (2013). Proteomic analysis of urinary exosomes in cardiovascular and associated kidney diseases by two-dimensional electrophoresis and LC-MS/MS. Methods in Molecular Biology, 1000, 209–220. doi:10.1007/978-1-62703-405-0_16.PubMedCrossRef

123.

Street, J. M., Barran, P. E., Mackay, C. L., Weidt, S., Balmforth, C., Walsh, T. S., et al. (2012). Identification and proteomic profiling of exosomes in human cerebrospinal fluid. Journal of Translational Medicine, 10, 5. doi:10.1186/1479-5876-10-5.PubMedPubMedCentralCrossRef

124.

Xiao, H., & Wong, D. T. (2012). Proteomic analysis of microvesicles in human saliva by gel electrophoresis with liquid chromatography-mass spectrometry. Analitica Chimica Acta, 723, 61–67. doi:10.1016/j.aca.2012.02.018.CrossRef

125.

Admyre, C., Johansson, S. M., Qazi, K. R., Filen, J. J., Lahesmaa, R., Norman, M., et al. (2007). Exosomes with immune modulatory features are present in human breast milk. Journal of Immunology, 179(3), 1969–1978.CrossRef

126.

Liang, B., Peng, P., Chen, S., Li, L., Zhang, M., Cao, D., et al. (2013). Characterization and proteomic analysis of ovarian cancer-derived exosomes. Journal of Proteomics, 80, 171–182. doi:10.1016/j.jprot.2012.12.029.PubMedCrossRef

127.

Hortin, G. L., & Sviridov, D. (2010). The dynamic range problem in the analysis of the plasma proteome. Journal of Proteomics, 73(3), 629–636. doi:10.1016/j.jprot.2009.07.001.PubMedCrossRef

128.

Fernando, S. A., & Wilson, G. S. (1992). Studies of the ‘hook’ effect in the one-step sandwich immunoassay. Journal of Immunological Methods, 151(1–2), 47–66.PubMedCrossRef

129.

Ioannidis, J. P. (2013). Biomarker failures. Clinical Chemistry, 59(1), 202–204. doi:10.1373/clinchem.2012.185801.PubMedCrossRef

130.

Gagne, J. P., Ethier, C., Gagne, P., Mercier, G., Bonicalzi, M. E., Mes-Masson, A. M., et al. (2007). Comparative proteome analysis of human epithelial ovarian cancer. Proteome Science, 5, 16. doi:10.1186/1477-5956-5-16.PubMedPubMedCentralCrossRef

131.

Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013). Evaluating cell lines as tumour models by comparison of genomic profiles. Nature Communications, 4, 2126. doi:10.1038/ncomms3126.PubMedPubMedCentralCrossRef

132.

Wei, B. R., Hoover, S. B., Ross, M. M., Zhou, W., Meani, F., Edwards, J. B., et al. (2009). Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS One, 4(10), e7670. doi:10.1371/journal.pone.0007670.PubMedPubMedCentralCrossRef

133.

He, Y., Wu, X., Liu, X., Yan, G., & Xu, C. (2010). LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker. Journal of Proteome Research, 9(12), 6180–6190. doi:10.1021/pr100822v.PubMedCrossRef

134.

Pitteri, S. J., JeBailey, L., Faca, V. M., Thorpe, J. D., Silva, M. A., Ireton, R. C., et al. (2009). Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One, 4(11), e7916. doi:10.1371/journal.pone.0007916.PubMedPubMedCentralCrossRef

135.

Tang, H. Y., Beer, L. A., Chang-Wong, T., Hammond, R., Gimotty, P., Coukos, G., et al. (2012). A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. Journal of Proteome Research, 11(2), 678–691. doi:10.1021/pr200603h.PubMedPubMedCentralCrossRef

136.

Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., et al. (2009). Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstetrics and Gynecology, 113(5), 1027–1037. doi:10.1097/AOG.0b013e3181a11c64.PubMedPubMedCentralCrossRef

137.

Harsha, H. C., & Pandey, A. (2010). Phosphoproteomics in cancer. Molecular Oncology, 4(6), 482–495. doi:10.1016/j.molonc.2010.09.004.PubMedPubMedCentralCrossRef

138.

Naumann, R. W., & Coleman, R. L. (2011). Management strategies for recurrent platinum-resistant ovarian cancer. Drugs, 71(11), 1397–1412. doi:10.2165/11591720-000000000-00000.PubMedCrossRef

139.

Yap, T. A., Carden, C. P., & Kaye, S. B. (2009). Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer, 9(3), 167–181. doi:10.1038/nrc2583.PubMedCrossRef

140.

Lee, J. M., Ledermann, J. A., & Kohn, E. C. (2014). PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Annals of Oncology, 25(1), 32–40. doi:10.1093/annonc/mdt384.PubMedPubMedCentralCrossRef

141.

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434(7035), 917–921. doi:10.1038/nature03445.PubMedCrossRef

142.

Dunn, L., & Demichele, A. (2009). Genomic predictors of outcome and treatment response in breast cancer. Molecular Diagnosis & Therapy, 13(2), 73–90. doi:10.2165/01250444-200913020-00002.CrossRef

143.

Yuan, Y., Van Allen, E. M., Omberg, L., Wagle, N., Amin-Mansour, A., Sokolov, A., et al. (2014). Assessing the clinical utility of cancer genomic and proteomic data across tumor types. [Computational Biology]. Nature Biotechnology, 32(7), 644–652. doi:10.1038/nbt.2940.PubMedPubMedCentralCrossRef

Title: Proteomics of ovarian cancer: functional insights and clinical applications
Authors: Mohamed A. Elzek
Karin D. Rodland
Publication date: 01-03-2015
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9547-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

HER2 expression status in diverse cancers: review of results from 37,992 patients

Erratum to: Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy

Maintenance chemotherapy in the management of epithelial ovarian cancer

Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies

Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?

The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal

Keynote webinar | Spotlight on antibody–drug conjugates in cancer